Dear community members,
Join us for the next Therapeutic Product Immunogenicity (TPI) Community Novel Modalities Subgroup meeting on Monday, September 30th, at 11:00 AM EST. Dr. Emmanuel Adu-Gyamfi from BMS will share his insights on immunogenicity assessment in AAV-based gene therapy.
The title of his presentation is: "Considerations for Immunogenicity Assessment in AAV-based (in vivo) Gene Therapy (GTx) Development."
Below is the meeting link, or you can email me at [email protected] to receive a personal Teams meeting calendar invite.
Best regards,
Kun and Karen
________________________________________________________________________________
Microsoft Teams Need help?
Join the meeting now
Meeting ID: 286 827 908 287
Passcode: QxssT3
Dial in by phone
+1 908-409-1059,,441267626# United States, Elizabeth
(833) 733-5876,,441267626# United States (Toll-free)
Find a local number
Phone conference ID: 441 267 626#
For organizers: 19_meeting_NmUyOTNiODUtM2VkMy00NjkzLTgyOTUtNTVkZjQyYmExMTYy@thread.v2&messageId=0&language=en-US" target="_blank" rel="noopener">Meeting options | Reset dial-in PIN
Audio for this meeting can be heard in the Microsoft Teams client. Please check your audio device settings before you join the call. If you see phone numbers above, you can use them to join the meeting's audio if necessary.
------------------------------
Kun Yang
Senior Principal Scientist
Bristol Myers Squibb
Princeton NJ
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------